Generic vs branded medicines in India: what the difference actually is

Ask a chemist in India for the generic version of a medicine and you may get one of three things: a strip from a different company with a different brand name, a plain strip labelled only with the chemical name, or a puzzled look. That confusion is not your fault. The words generic and branded mean something different here from what they mean in most of the countries whose debates about them you may have read.

This post explains what those words mean in the Indian market, how a medicine gets permission to be sold, what the rules say about doctors prescribing by generic name, how the Jan Aushadhi stores and price controls work, and how to raise the question with your doctor. It does not tell you whether any particular switch is right for you. That is a question for the doctor who prescribed the medicine, or the pharmacist dispensing it, who know what you are taking and why.

What generic and branded mean in India

Every medicine has an active ingredient with an international non-proprietary name — paracetamol, metformin, amoxicillin. When a new molecule is invented, the company that developed it usually sells it under a brand name while it holds a patent. Once the patent ends, or where it never applied, other manufacturers may make the same molecule. Those later versions are what the world calls generics.

India is unusual because almost the entire market is made of these later versions, and most of them are still sold under brand names. A single common molecule may be marketed by dozens of companies, each with its own name, packaging and price. These are usually called branded generics. A smaller segment sells the same molecules under the chemical name alone, with little or no marketing; these are often called unbranded or trade generics, and they include the medicines sold through Jan Aushadhi stores.

The practical consequence is that the choice in India is rarely between an original and a copy. It is usually between several copies of the same molecule, made by different manufacturers, at very different prices. The price difference is mostly marketing, distribution margins and brand reputation. Whether there is any difference in quality depends on the manufacturer, not on whether the strip carries a brand name.

How a medicine is approved, and what bioequivalence means

Medicines in India are regulated under the Drugs and Cosmetics Act, 1940, and its rules. Approval is split. The Central Drugs Standard Control Organisation, headed by the Drugs Controller General of India, approves new drugs and clinical trials. Licences to manufacture medicines that are already established are granted by state drug licensing authorities, which also inspect factories and pharmacies in their state.

Bioequivalence is the test that matters most for generics. A bioequivalence study checks whether a generic version releases the active ingredient into the bloodstream at a rate and extent close enough to a reference product that it can be expected to behave the same way. For a period after a molecule is first approved in India it is treated as a new drug, and later applicants need central approval, usually with bioequivalence data. For older molecules licensed by the states, the historical gap was that such data was not required. An amendment to the rules in April 2017 made bioequivalence studies compulsory for certain categories of oral generic medicines, but the requirement does not extend to every older molecule and every dosage form.

Quality also depends on manufacturing standards and on enforcement. Medicines must meet the standards in the Indian Pharmacopoeia or another recognised standard, factories must follow good manufacturing practice, and regulators test samples drawn from the market. CDSCO publishes regular alerts listing samples found not of standard quality. Those lists include products from large, well-known companies as well as small ones, which is a reminder that a familiar brand name is not the same thing as a quality guarantee.

What the rules say about doctors prescribing generics

The professional conduct regulations that bind registered doctors date from 2002. In their original form they said a physician should, as far as possible, prescribe drugs by generic name. An amendment notified in September 2016 strengthened the wording: every physician should prescribe drugs with generic names, legibly and preferably in capital letters, and should ensure rational prescription and use of drugs.

In August 2023 the National Medical Commission notified new professional conduct regulations which went further, requiring generic prescribing and treating violations as professional misconduct. After objections from doctors' associations — including concerns about the quality of some generics on the market — the commission put those regulations in abeyance later that month, and directed that the 2002 regulations continue to apply. As of December 2025 the health ministry was still citing the 2002 regulations in Parliament as the operative rule on generic prescribing, and the 2023 regulations had not been brought back into force.

Separately, central government hospitals and CGHS doctors have been directed by the Directorate General of Health Services to prescribe generic medicines. Practice in private clinics varies widely. Many doctors write a brand name; some write the generic name with a brand in brackets; a smaller number write only the generic name. Under the regulations, the generic name should be on the prescription whatever else is.

Jan Aushadhi: the government's generic stores

The Pradhan Mantri Bhartiya Janaushadhi Pariyojana is a scheme of the Department of Pharmaceuticals, run through the Pharmaceuticals and Medical Devices Bureau of India. It began as the Jan Aushadhi scheme in 2008 and was renamed in 2016. It sells unbranded generic medicines and surgical items through dedicated stores called Jan Aushadhi Kendras, most of them run by private operators, NGOs or institutions under the scheme's terms.

• Scale: nearly 17,000 Kendras were operating by November 2025, according to the government, with a stated target of 25,000 by March 2027.
• Range: the product basket covers over 2,000 medicines and 315 surgical items across 29 therapeutic groups. Not every store stocks every item.
• Price: the government says its medicines are priced 50 to 80 percent below branded equivalents. The saving on any particular medicine varies.
• Quality: the scheme says it buys only from manufacturers with WHO-GMP certification and tests each batch at NABL-accredited laboratories before distribution. (What NABL and NABH accreditation mean.)

The weak points are availability and continuity. Stores sometimes run out of a particular medicine, which matters for anyone on long-term treatment. Some medicines are not in the basket at all. And the scheme's stores are thinner on the ground in some districts than others. The scheme publishes a mobile app that lists stores and products and compares prices with branded equivalents, which is the quickest way to check before making a trip. And you are free to fill a prescription at any licensed pharmacy you choose, including a Kendra — choice of pharmacy is one of your rights as a patient.

Price control: NPPA and the DPCO

Medicine prices in India are partly controlled. The National Pharmaceutical Pricing Authority enforces the Drugs (Prices Control) Order, 2013. Medicines on the National List of Essential Medicines — the current list dates from November 2022 — are scheduled formulations, and NPPA fixes a ceiling price for them. Any brand of that medicine, in that strength and form, must be sold at or below the ceiling, plus GST. Ceiling prices are revised each April in line with the wholesale price index.

Medicines not on the list are non-scheduled. A manufacturer sets its own price at launch, but may not raise the maximum retail price by more than ten percent in any twelve months. Nobody, including a chemist, may sell any medicine above the MRP printed on the pack. If you are charged more, NPPA accepts complaints about overcharging.

Price control narrows the gap but does not close it. A ceiling sets the most a brand can charge, not the least, and many commonly used combinations fall outside the essential list. Comparing the MRP of two strips containing the same molecule, strength and form is still the simplest way to see what you are paying for the brand.

How to ask your doctor or pharmacist

1. Ask for the generic name to be writtenIf the prescription shows only a brand, ask the doctor to add the generic name and strength. The regulations already expect it, and it lets you compare options. More on what a prescription should contain is in prescriptions and pharmacies in India.
2. Ask whether a substitute is acceptable for this medicineSome doctors are relaxed about substitution for most medicines and specific about a few. Ask directly: is there any reason I should stay on this particular brand? The answer is part of the treatment decision and belongs with the prescriber.
3. Ask the pharmacist to match exactlyIf a substitute is acceptable, ask the pharmacist for the same molecule, the same strength and the same form — a sustained-release tablet is not interchangeable with an ordinary one. Check the composition printed on both packs before you pay.
4. Tell your doctor if you switchIf you change manufacturer, mention it at the next visit, along with anything you noticed. It keeps the record accurate and lets the doctor judge whether the change matters for you.

None of this is a reason to distrust a doctor who prescribes a brand. Many have reasons based on experience with a particular manufacturer. But it is reasonable to ask, and a doctor who will not explain is worth noting. Cost questions belong at the start of care, not the end; what doctors charge in India covers the consultation side, and how to choose a doctor in India covers the rest.

Where the system falls short

The honest summary is that the generic system in India is cheap, large and uneven. The split between central approval and state licensing means standards of scrutiny have historically differed by molecule and by state. The bioequivalence requirement is narrower than many patients assume. Enforcement capacity in state drug control departments is limited. And the incentives in the market — trade margins, promotion to doctors and chemists — do not always reward the cheapest good product.

Against that, the price difference is real and for people paying out of pocket for long-term treatment it can be large. The sensible position sits between blind trust in brands and blind faith in the cheapest strip: ask for the generic name, ask whether substitution is acceptable for this medicine, buy from a licensed pharmacy, and keep your doctor informed. You can find a doctor willing to have that conversation by browsing doctors by city and speciality — general practitioners and physicians in the specialties index are often the best place to start — and read our editorial policy for how we handle health information.

General information about how healthcare in India is organised and regulated, current at 8 Oct 2026. Not advice about your situation, and not for emergencies — call 108. Errors can be reported through the corrections process.